Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $65.00.

Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG’s strategic advancements and potential for growth. The recent collaboration with Sirius Therapeutics to develop and commercialize SRSD107, a next-generation siRNA candidate, diversifies Crispr’s pipeline beyond gene editing. This partnership not only broadens the company’s cardiovascular franchise but also enhances its ability to target a wider range of indications through siRNA delivery.
Furthermore, the initial Phase 1 data for SRSD107 is promising, showing significant FXI inhibition with favorable safety profiles, which could be crucial for arterial indications. The financial structure of the collaboration, with Crispr providing cash and equity upfront and sharing development costs and profits, reflects a balanced risk-reward scenario. Kapoor’s valuation analysis, based on a discounted cash flow model, supports a 12-month price target of $65, considering the potential success of Crispr’s pipeline and the strategic benefits of the Sirius partnership.

Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ionis Pharmaceuticals, and Summit Therapeutics. According to TipRanks, Kapoor has an average return of -25.7% and a 24.71% success rate on recommended stocks.